▎ 摘　　要

NOVELTY - Method for early stage detection of pathology in patient involves administering pathology-specific antibody-coated nanoparticle into patient's circulation, where pathology-specific antibody-coated nanoparticle comprises nanoparticle binds to pathology-specific antibody; allowing time interval for pathology-specific antibody of antibody-coated nanoparticle to attach to specific antigen in circulating extracellular vesicle or cell; exciting antibody-coated nanoparticle with energy source in conjunctival blood vessel non-invasively in patient to elicit nanoparticle-specific wavelength of light response from antibody-coated nanoparticle attached to circulating extracellular vesicle or cell indicating early stage pathology in patient due to presence of specific antigen in which pathology-specific antibody of antibody-coated nanoparticle is bind, where early stage pathology is located in portion of body of patient other than conjunctiva. USE - Method for early stage detection of pathology in patient used for recognition of neoplastic process without producing clinical symptom in patient, where early stage pathology which is selected from cancer, infection, inflammation, metabolic disorder, genetic disease, neurodegenerative disease, ocular disease, and combinations (all claimed); treating tumor such as retinoblastoma, glioblastoma, medulloblastoma, acoustic neuroma, spinal cord tumor, peripheral nerve tumor, choroidal melanoma, skin melanoma, mesenchymal cell tumor, tumor of ectodermal origin, basal cell carcinoma, squamous cancer, etc. ADVANTAGE - The method helps in reducing stimulus for creating neovascular tissue or exhausting T-cell action against tumor cells; eliminates tumor mass and metastatic lesion of circulating tumor cells along with exosomes carrying same biomarkers as original tumor; inhibits inflammatory processes, reduces tumor growth factor (TGF)-β formation, block cell migration, and inhibit metastatic spread of tumors. DETAILED DESCRIPTION - Method for early stage detection of pathology in patient involves administering pathology-specific antibody-coated nanoparticle into patient's circulation, where pathology-specific antibody-coated nanoparticle comprises nanoparticle binds to pathology-specific antibody; allowing time interval for pathology-specific antibody of antibody-coated nanoparticle to attach to specific antigen in circulating extracellular vesicle or cell; exciting antibody-coated nanoparticle with energy source in conjunctival blood vessel non-invasively in patient to elicit nanoparticle-specific wavelength of light response from antibody-coated nanoparticle attached to circulating extracellular vesicle or cell indicating early stage pathology in patient due to presence of specific antigen in which pathology-specific antibody of antibody-coated nanoparticle is bind, where early stage pathology is located in portion of body of patient other than conjunctiva, and antibody-coated nanoparticle is conjugated to gene which is able to modify genetic composition of target cells in which antibody coated nanoparticle is targeted; and imaging and quantifying nanoparticle-specific wavelength of light response in conjunctival blood vessel for detection of early stage pathology before mass associated with early stage pathology growing beyond predetermined diameter and causing clinical symptom. An INDEPENDENT CLAIM is included for a recognition method for early stage of neoplastic process without producing clinical symptom in patient, which involves: (a) defining change in tissue of patient, change indicating early stage lesion or disease process in at least one cell in tissue; (b) administering plurality of nanoparticles to patient, where nanoparticles, which binds to pathology-specific antibody against protein in early stage lesion or disease process to result in functionalized nanoparticles, functionalized nanoparticles coated with thermosensitive polymer contains medicament for therapy of early stage lesion or disease process; (c) interrogating circulating cellular and extracellular vesicles in patient's blood using photoacoustic spectroscopic system and optical spectroscopic fundus camera equipped with laser which is focused on conjunctival blood vessel of patient, where early stage lesion or disease process is located in portion of body of patient other than conjunctiva; (d) recording, imaging, quantifying, or analyzing patient's circulating cells and extracellular vesicles non-invasively according to functionalized nanoparticles in conjunctival blood vessel of patient; (e) measuring plasma glucose level of patient in conjunctival blood vessel using terahertz time-domain spectroscopy; and (f) using system to increase temperature of functionalized nanoparticles to temperature of 42-43℃ to release medicament from thermosensitive polymer to treat early stage lesion or disease process.